Cardiovascular Effects and Tolerability of GLP

Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.

Glucagon like peptide-1 ( GLP-1 ) receptor agonists are well established drugs for the treatment of type 2 diabetes (T2D). In addition to glycemic control, GLP-1 receptor agonists have beneficial other effects . They act by binding to GLP-1 receptors , ...
Key Details About Cardiovascular Effects Of Glp 1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) provide proven cardiovascular benefits in type 2 diabetes mellitus (T2DM) and heart failure, but their effects in patients with peripheral artery disease (PAD) remain unclear. PAD is common in T2DM and increases the risk of adverse cardiovascular and limb outcomes.
Abstract Therapy with glucagon-like peptide 1 ( GLP1 ) receptor agonists has raised great interest for its beneficial cardiovascular effects in preventing atherosclerosis and heart failure-related outcomes.

GLP1RAs in Clinical Practice
Quick Takes Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines. Clinicians should be vigilant for gastrointestinal tract adverse effects in patients using ...
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate how GLP-1 agonists help lower cardiovascular risk for conditions, including atherosclerosis, heart failure, stroke, and ...

The benefits of GLP1 receptors in cardiovascular diseases
The aim of this article is to provide a comprehensive review of GLP-1 receptor agonists impact on cardiovascular outcomes and risk reduction. In the last decade, several cardiovascular outcomes trials (CVOT) have been conducted in order to explore cardiovascular benefit of GLP-1 receptor agonists .
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...
Key Details About Cardiovascular Effects Of Glp 1 Receptor Agonists
Patients with type 2 diabetes are at high risk for development of cardiovascular disease, including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large cardiovascular outcome trials with novel glucose-lowering agents, namely SGLT2i (SGLT2 inhibitors) and GLP-1 RA ( GLP-1 receptor agonists ), have demonstrated robust and significant reductions of major adverse ...






Glucagon-like peptide 1 ( GLP1 ) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus. In this Review, Ussher and Drucker discuss the ...